All the news Showing 9 of 129 articles from: Health services, policy and advocacyGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Early hepatitis C treatment may not be cost-saving in France - but early diagnosis will save money Keith Alcorn / 07 May 2013 Treating hepatitis C earlier than recommended by current French and European treatment guidelines, before the development of severe liver fibrosis, may not result in substantial cost savings even if the price of direct-acting ... Compassionate access to new hepatitis C drugs an "emergency" for European patients Keith Alcorn / 30 April 2013 European governments must move quickly to ensure that compassionate use arrangements are put into place to allow access to new hepatitis C drugs for people with cirrhosis, advocates and doctors said at ... Study shows the high human and economic burden of HCV infection in Europe Michael Carter / 24 April 2013 A large European study has provided valuable insights into the high economic and human costs of infection with hepatitis C virus (HCV). Published in BMC Gastroenterology, the research showed that HCV infection was ... Liver disease a major cause of illness and death across the EU: action needed to save lives Michael Carter / 10 April 2013 Liver disease is the cause of a considerable burden of illness across the European Union (EU), investigators report in The Journal of Hepatology. The authors calculate that 170,000 deaths each year are attributable ... Hepatitis B treatment and care in the UK need to evolve to keep pace with the global epidemic Michael Carter / 09 January 2013 “Persistent HBV [hepatitis B virus] infection has changed its face in the UK,” research published in the online edition of Clinical Infectious Diseases shows. The study found considerable diversity in viral genotype and ... Which patients should be prioritised for new hepatitis C treatments? Rob Camp / 23 November 2012 Younger patients with advanced liver disease caused by hepatitis C should be prioritised for treatment with newly licensed directly acting antivirals to achieve the biggest reductions in ill health and hospitalisation, according to ... Antiretroviral rollout provides a model for efforts to expand hepatitis C treatment and care in resource-limited settings Michael Carter / 27 March 2012 The rollout of antiretroviral therapy in resource-limited settings provides a model for efforts to increase access to hepatitis C treatment and care in similar settings, investigators argue in the online edition of Clinical ... Hepatitis C protease inhibitor therapy cost-effective in some circumstances Michael Carter / 21 February 2012 First-line hepatitis C therapy which includes a protease inhibitor can be cost-effective, investigators show in the Annals of Internal Medicine. The study showed that a triple combination of drugs, including the cheaper ... With special training, effective and safe hepatitis C therapy can be provided in primary care Michael Carter / 23 June 2011 Specially trained primary care providers can offer effective and safe treatment for hepatitis C infection, US investigators report in the New England Journal of Medicine. Rates of sustained virological response were the ... ← Prev1...910111213Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Access to medicines & diagnostics Hepatitis C elimination Models of care Finance, funding & health economics National policy European policy International policy Activism and civil society Pharmaceutical industry Social issues Conference news Email bulletin archive